Advertisement

Reactions Weekly

, Volume 1730, Issue 1, pp 180–180 | Cite as

Ipilimumab

Fulminant type 1 diabetes mellitus and pan-hypopituitarism following off-label use: case report
Case report
  • 19 Downloads

Reference

  1. Tsiogka A, et al. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Research 27: 524-525, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1097/CMR.0000000000000384 - AustriaCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations